Modeling and Simulation Move Downstream

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-15-2016
Volume 2016 eBook
Issue 1
Pages: s22-s25

This article explores two commercial platforms, and touches on a new program underway in the UK.

Today, some of the most advanced computer-based models are being used for early research.  However, the move to continuous processing has stimulated interest in process optimization and control. This article explores two commercial platforms, and touches on a new program underway in the UK.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.
Articles in this issue
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Optimizing Tablet Compression
Optimizing Tablet Compression
Excipient-Quality-and-Selection.jpg
Excipient Quality and Selection
Pages-from-PTeBook0316_034-038_continuous_freeman.jpg
Filling the Analysis Gap in the Move to Continuous Processing
Pages-from-PTeBook0316_046-054_Generics_DMFs_Subburaj.jpg
Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances
Pages-from-PTEBook0316_022-025_Modeling.jpg
Modeling and Simulation Move Downstream
Unifying-Excipient-Databases.jpg
Unifying Excipient Databases
Pages-from-PTeBook0316_020-021_Capsugel.jpg
Establishing a New Performance Standard for HPMC Capsules
Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Incyte, Genesis Therapeutics to Use AI Platform to Discover Small Molecule Compounds

Patrick Lavery
February 21st 2025
Article

The collaboration will utilize Genesis’ proprietary AI platform, initially focusing on targets selected by Incyte.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Google Launches AI Co-Scientist System

Susan Haigney
February 20th 2025
Article

The AI co-scientist is a multi-agent AI system that can work as a virtual scientific collaborator.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

MMS Acquires Exploristics and Its Flagship Modeling and Simulation Platform

Patrick Lavery
February 14th 2025
Article

In seeking a data-driven approach to efficient drug development, MMS aims to enhance its capabilities in advanced clinical trial design, innovative statistics, and data science with the acquisition.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Axplora Announces €50 Million Investment in GLP-1 Manufacturing in France

Patrick Lavery
February 13th 2025
Article

This site was previously the beneficiary of a €7.3 million (US$7.6 million) investment, made in 2022, earmarked for the production of HPAPIs to treat cancer.